Lipoprotein(a) - Lp(a) - is an hepatically synthesized lipoprotein, structurally similar to low-density-lipoprotein, and an important marker for cardiovascular risk. Lp(a) plasma concentrations are genetically determined and can hardly be modified by diet, exercise or oral drugs. Lp(a) concentration should be tested at least once per life. The current treatment for high Lp(a) is early intensive risk factor management with optimal lowering of LDL-cholesterol. Potent new RNA-targeting therapies are currently assessed in clinical trials and may be available in a couple of years.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668486 | PMC |
| http://dx.doi.org/10.1055/a-1516-2701 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Class IIa histone deacetylase (HDAC) inhibitor TMP269 suppresses lumpy skin disease virus replication by regulating host lysophosphatidic acid metabolism.
J Virol
January 2025
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou University, Lanzhou, China.
Lumpy skin disease virus (LSDV) infection poses a significant threat to global cattle farming. Currently, effective therapeutic agents are lacking. TMP269, a small molecule inhibitor of class IIa histone deacetylase inhibitor, plays a vital role in cancer therapy.
View Article and Find Full Text PDFStrengths use and thriving at work among nurses: a latent profile and mediation analysis.
BMC Nurs
January 2025
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
Background: The ability to thrive at work has been demonstrated to be closely linked to the development of nurses.Effective utilization of strengths and maintaining hope are essential elements for clinical nurses' ability to flourish in their roles. Nevertheless, the relationship between strengths use, hope, and thriving at work remains underexplored.
View Article and Find Full Text PDFVariation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size.
J Clin Lipidol
December 2024
Center for the Prevention of Cardiovascular Disease, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine. 530 First Avenue, HCC5, New York, NY 10016, USA. Electronic address:
Background: Lipoprotein(a) [Lp(a)] is a driver of residual cardiovascular risk. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) decrease Lp(a) with significant heterogeneity in response. We investigated contributors to the heterogeneous response.
View Article and Find Full Text PDFPrevalence of Lp(a) in a real-world Portuguese cohort: implications for cardiovascular risk assessment.
Lipids Health Dis
January 2025
Department of Endocrinology, Diabetes and Metabolism, Local Health Unit of Santo António, Largo Professor Abel Salazar, Porto, 4099-001, Portugal.
Background: Cardiovascular disease (CVD) is a major cause of mortality worldwide, necessitating more refined strategies for risk assessment. Recently, lipoprotein(a) [Lp(a)] has gained attention for its distinctive role in atherosclerosis, yet its prevalence and impact for cardiovascular risk assessment are not well-documented in the Portuguese population. This study aimed to characterize Lp(a) levels in a real-world Portuguese cohort, investigating its prevalence and association with CVD risk.
View Article and Find Full Text PDFThe global, regional, and national disease burden of colorectal cancer attributable to low physical activity from 1990 to 2021: an analysis of the Global Burden of Disease Study 2021.
Int J Colorectal Dis
January 2025
School of Medicine, University of Galway, Galway, Ireland.
Objectives: This study aims to estimate the spatiotemporal variation in the burden of colorectal cancer (CRC) attributable to low physical activity (LPA) at global, regional, and national levels from 1990 to 2021.
Study Design: Cross-sectional study.
Methods: Annual data on deaths of CRC related to LPA, age-standardized mortality rate (ASMR), disability-adjusted life years (DALYs), and the age-standardized DALYs rate (ASDR) for 204 countries and territories from 1990 to 2021 was extracted from the Global Health Data Exchange website.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!